RISK-BASED INSPECTION APPROACH IN PHARMACEUTICAL REGULATORY AFFAIRS: A MODERN STRATEGY FOR QUALITY COMPLIANCE

Abstract

Global pharmaceutical authorities have used risk-based inspection (RBI), a modern and science-driven regulatory strategy, to improve drug quality, safety, and efficacy while making the best use of regulatory resources. RBI focuses on discovering, assessing, and prioritizing possible risks related to pharmaceutical manufacturing processes, facilities, and products, in contrast to typical inspection systems that depend on set schedules. With a focus on risk assessment techniques, inspection planning tactics, and compliance evaluation procedures, this project offers a thorough examination of the concepts and principles that underpin RBI. The study examines a number of risk criteria that regulatory authorities use to classify facilities into different risk levels, such as product complexity, manufacturing procedures, compliance history, recall incidents, and patient impact. Additionally, it looks at how key regulatory bodies including the USFDA, EMA, and CDSCO have implemented RBI, highlighting the models, instruments, and regulatory requirements of each. Additionally, a critical analysis is conducted of how internationally recognized guidelines specifically, Quality Risk Management principles support RBI practices. Furthermore, this work assesses how risk assessment tools like Hazard Analysis and Critical Control Points (HACCP) and Failure Mode and Effects Analysis (FMEA) are integrated in both industrial and regulatory contexts. There is a thorough discussion of how RBI might increase Good Manufacturing Practice (GMP) compliance, decrease regulatory burden, and improve inspection efficiency. Additionally covered are issues related to data dependability, implementation difficulty, and the requirement for qualified staff.  Overall, the study's conclusions indicate that RBI greatly enhances regulatory decision-making and guarantees a more focused and efficient inspection procedure, which eventually helps to improve patient safety and harmonize pharmaceutical regulations worldwide.